Redmile Group, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $19.9 Million - $31.3 Million	-425,480 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$37.41 - $62.25 $67.2 Million - $112 Million	-1,795,564 Reduced 80.84%	425,480 $22.6 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $6.97 Million - $10.3 Million	-195,362 Reduced 8.08%	2,221,044 $96.4 Million
Q4 2020 Feb 16, 2021	SELL	$31.71 - $57.97 $507,423 - $927,635	-16,002 Reduced 0.66%	2,416,406 $126 Million
Q3 2020 Nov 16, 2020	BUY	$27.03 - $47.97 $20.8 Million - $37 Million	771,203 Added 46.42%	2,432,408 $79.5 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $38.5 Million - $91 Million	1,661,205 New	1,661,205 $79.8 Million

148

69.8M

61.8K

6.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $214M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.